Intramuscular testosterone undecanoate for the treatment of male hypogonadism–review of recent data

Jockenhövel, 2004 Mooradian, 1987, Biological actions of androgens, Endocr Rev, 8, 1, 10.1210/edrv-8-1-1 Alexandersen, 2004, The aging male: testosterone deficiency and testosterone replacement. An up-date, Atherosclerosis, 173, 157, 10.1016/S0021-9150(03)00242-9 von Eckardstein, 2003, Testosterone and atherosclerosis, Growth Horm IGF Res, 13, S72, 10.1016/S1096-6374(03)00059-5 Bhasin, 1998, Issues in testosterone replacement in older men, J Clin Endocrinol Metab, 83, 3435, 10.1210/jc.83.10.3435 Behre, 1998, Comparative pharmacokinetics of testosterone esters, 329 Meikle, 1992, Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men, J Clin Endocrinol Metab, 74, 623, 10.1210/jc.74.3.623 Nieschlag, 1976, Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men, Horm Res, 7, 138, 10.1159/000178721 Nieschlag, 2005, Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations, Eur Urol, 48, 1, 10.1016/j.eururo.2005.04.027 Schurmeyer, 1984, Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men, Int J Androl, 7, 181, 10.1111/j.1365-2605.1984.tb00775.x Schubert, 2004, Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism, J Clin Endocrinol Metab, 89, 5429, 10.1210/jc.2004-0897 Nieschlag, 1999, Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal men, Clin Endocrinol (Oxf), 51, 757, 10.1046/j.1365-2265.1999.00881.x Behre, 1999, Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies, Eur J Endocrinol, 140, 414, 10.1530/eje.0.1400414 von Eckardstein, 2002, Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study, J Androl, 23, 419 Sommer, 2002, The effect of long-term testosterone replacement therapy on prostate specific antigen and prostate volume in hypogonadal men – results of a prospective study, Eur Urol, 1, 61, 10.1016/S1569-9056(02)80231-7 Behre, 1992, Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception, J Clin Endocrinol Metab, 74, 84, 10.1210/jc.74.1.84 Huebler, 2001, Effect of a new long-acting testosterone undecanoate (TU) formulation vs. testosterone enanthate (TE) for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men, Int J Impot Res, 13, S31 Huebler, 2002, Effect of a new long-term treatment with a new sustained-action testosterone undecanoate (TU) formulation for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men, Int J Impot Res, 14, S51 Foresta, 2004, Role of androgens in erectile function, J Urol, 171, 2358, 10.1097/01.ju.0000124323.02868.68 Morales, 2004, Endocrine aspects of sexual dysfunction in men, J Sex Med, 1, 69, 10.1111/j.1743-6109.2004.10111.x Shabsigh, 1997, The effects of testosterone on the cavernous tissue and erectile function, World J Urol, 15, 21, 10.1007/BF01275152 Azadzoi, 1992, Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone, J Urol, 147, 220, 10.1016/S0022-5347(17)37201-4 Burnett, 2004, Novel nitric oxide signaling mechanisms regulate the erectile response, Int J Impot Res, 16, S15, 10.1038/sj.ijir.3901209 Traish, 1999, Effects of castration and androgen replacement on erectile function in a rabbit model, Endocrinol, 140, 1861, 10.1210/en.140.4.1861 Traish, 2003, Effects of medical or surgical castration on erectile function in an animal model, J Androl, 24, 381, 10.1002/j.1939-4640.2003.tb02686.x Shen, 2003, Effect of androgen deprivation on penile ultrastructure, Asian J Androl, 5, 33 Traish, 2005, Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiency, J Androl, 26, 242, 10.1002/j.1939-4640.2005.tb01091.x Yassin, 2006, Dramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literature, Andrologia, 38, 34, 10.1111/j.1439-0272.2006.00705.x Yassin A, Saad F. Modulation of erectile function with long-acting testosterone injection (Nebido©) i.m. in hypogonadal patients. Abstract P045. In: International Congress of Andrology, 2005. Seoul: International Journal of Andrology; 2005. Greenstein, 2005, Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed?, J Urol, 173, 530, 10.1097/01.ju.0000149870.36577.05 Shabsigh, 2004, Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone, J Urol, 172, 658, 10.1097/01.ju.0000132389.97804.d7 Kalinchenko, 2003, Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone, Aging Male, 6, 94, 10.1080/713604767 Yassin, 2003, Kombinationstherapie bei erektiler Dysfunktion mit Testosteron und Tadalafil bei hypogonadalen Patienten, die auf Tadalafil als Monotherapie nicht ansprechen, Blickpunkt der Mann, 2, 37 Zitzmann M, von Eckardstein S, Saad F, Nieschlag E. Long-term experience with injections of testosterone undecanoate for substitution therapy in hypogonadal men. In: 87th Annual Meeting of the Endocrine Society, 2005 June 4–7. San Diego, CA: Endocrine Society;2005. p. 306.